• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.

作者信息

Sriskandarajah Priya, Pawlyn Charlotte, Mohammed Kabir, Dearden Claire E, Davies Faith E, Morgan Gareth J, Boyd Kevin D, Kaiser Martin F

机构信息

a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.

b The Institute of Cancer Research , London , UK.

出版信息

Leuk Lymphoma. 2017 Feb;58(2):494-497. doi: 10.1080/10428194.2016.1198957. Epub 2016 Jul 20.

DOI:10.1080/10428194.2016.1198957
PMID:27439571
Abstract
摘要

相似文献

1
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.泊马度胺在“真实世界”研究中对复发/难治性骨髓瘤患者的疗效和耐受性：皇家马斯登医院的经验
Leuk Lymphoma. 2017 Feb;58(2):494-497. doi: 10.1080/10428194.2016.1198957. Epub 2016 Jul 20.
2
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.泊马度胺治疗复发/难治性多发性骨髓瘤的疗效、安全性和成本。
Eur J Haematol. 2018 May;100(5):518-525. doi: 10.1111/ejh.13039. Epub 2018 Mar 6.
3
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.泊马度胺治疗经验：一种用于复发难治性多发性骨髓瘤患者的免疫调节药物有效治疗方法。
Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.
4
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.在一项“真实世界”研究中，泊马度胺在复发性/难治性多发性骨髓瘤中的疗效和安全性：波兰骨髓瘤小组的经验。
Eur J Haematol. 2018 Sep;101(3):354-361. doi: 10.1111/ejh.13106. Epub 2018 Jul 12.
5
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.泊马度胺治疗复发难治性骨髓瘤的澳大利亚“真实世界”经验。
Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12.
6
Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.泊马度胺治疗多次预处理的难治性多发性骨髓瘤：一例报告
Future Oncol. 2017 Feb;13(5s):7-9. doi: 10.2217/fon-2016-0460.
7
Pomalidomide: when expectations are understated.泊马度胺：当期望被低估时。
Future Oncol. 2017 Feb;13(5s):1-2. doi: 10.2217/fon-2016-0559.
8
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.苯达莫司汀、泊马度胺和地塞米松用于复发和/或难治性多发性骨髓瘤
Blood Cancer J. 2018 Jul 31;8(8):71. doi: 10.1038/s41408-018-0104-5.
9
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.泊马度胺治疗高危复发难治性多发性骨髓瘤的II期研究
Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25.
10
Desensitization to lenalidomide in a patient with relapsed multiple myeloma.一名复发多发性骨髓瘤患者对来那度胺脱敏治疗的情况
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):162-5. doi: 10.1016/j.clml.2012.09.003. Epub 2012 Oct 26.

引用本文的文献

1
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.多发性骨髓瘤患者临床试验之外：真实世界结果的批判性综述
Front Oncol. 2022 May 11;12:844779. doi: 10.3389/fonc.2022.844779. eCollection 2022.
2
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.泊马度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者：非干预性研究 POSEIDON 的最终结果及其与关键性 3 期临床试验的比较。
Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15.
3
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
泊马度胺和地塞米松长期疾病控制对复发/难治性多发性骨髓瘤患者的临床益处
J Clin Med. 2019 Oct 16;8(10):1695. doi: 10.3390/jcm8101695.
4
Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma.泊马度胺在复发/难治性多发性骨髓瘤患者中的真实世界使用的耐受性和安全性。
Mol Clin Oncol. 2019 Feb;10(2):293-298. doi: 10.3892/mco.2018.1775. Epub 2018 Nov 27.
5
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.泊马度胺联合或不联合地塞米松治疗日本复发/难治性多发性骨髓瘤：关西骨髓瘤论坛的回顾性分析
Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29.
6
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.泊马度胺治疗多发性骨髓瘤：设计、研发及治疗地位
Drug Des Devel Ther. 2017 Aug 22;11:2399-2408. doi: 10.2147/DDDT.S115456. eCollection 2017.